The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ensure supply.

Viking Therapeutics, a mid-cap biotech, made waves after it reported excellent phase 2 results for an investigational ...

It's also running a phase 2 study for the oral version of its lead candidate. Elsewhere, Viking is developing another ...

The research not only enhances understanding of Viking-era health but also underscores the challenges people faced without modern medicine. Severe infections, joint diseases, and dental problems ...